Vaccitech to Present at Upcoming October Investor & Scientific Conferences
2022年10月4日 - 5:30AM
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical
company engaged in the discovery and development of novel
immunotherapeutics and vaccines, today announced that the Company’s
Chief Scientific Officer, Dr. Thomas G. Evans, Vice President,
Corporate Development, Nick Fullenkamp, Senior Vice President,
Synthetic Immunotherapies, Dr. Geoffrey Lynn, and Senior Research
Development Scientist, Dr. Hugh Welles will be participating in the
following conferences in October.
Event: |
Maryland Life Sciences
Bio Innovation Conference, Bethesda |
Date: |
Monday, October 3 – Tuesday,
October 4 |
Panel: |
Emerging Vaccine Opportunities
in Modulating the Immune System |
Participant: |
Dr. Geoffrey Lynn |
Time: |
3:30 – 4:15 p.m. EDT on
Monday, October 3 |
|
|
Event: |
World Vaccine
Congress, Barcelona, Spain |
Date: |
Tuesday, October 11 – Friday,
October 14 |
Presentation: |
A Novel Approach for Focusing
Antibody Responses as a Pan-Coronavirus Vaccine |
Participant: |
Dr. Hugh Welles |
Time: |
10:45 a.m. EDT on Wednesday,
October 12 |
|
|
Presentation: |
Novel Cancer Vaccine Program:
Updates HPV Cancer Vaccine |
Participant: |
Dr. Geoffrey Lynn |
Time: |
7:00 a.m. EDT on Friday,
October 14 |
|
|
Event: |
HC Wainwright
3rd Annual Hepatitis B Virus
Conference, Virtual |
Date: |
Tuesday, October 18 |
Presentation: |
Fireside Chat |
Participant: |
Dr. Thomas G. Evans |
Time: |
09:30 a.m. EDT on Tuesday,
October 18 |
|
|
Event: |
BIO-Europe,
Leipzig, Germany |
Date: |
Monday, October 24 –
Wednesday, October 26 |
Attending: |
Nick Fullenkamp |
|
Available to participate in
1x1 partnering meetings |
About Vaccitech plcVaccitech (“the Company”) is
a clinical-stage biopharmaceutical company engaged in the discovery
and development primarily of novel immunotherapies for the
treatment of chronic infectious diseases, cancer, autoimmunity and
diseases where the T cell arm of the immune system is believed to
play an important role. The company’s proprietary platforms include
modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other
viral vectors including the well-validated Modified Vaccinia Ankara
(MVA) and synthetic nano-particle technologies (SNAPvax™ and
Syntholytic™). The combination of different technologies in a mix
and match approach (heterologous prime-boost) consistently
generates significantly higher magnitudes of T cells compared with
other technologies and approaches. The company has a broad pipeline
of both clinical and preclinical stage therapeutic programs to
treat solid tumors, chronic viral infections, as well as a few
prophylactic viral vaccine programs. Vaccitech co-invented a
COVID-19 vaccine with the University of Oxford, now approved for
use in many territories and exclusively licensed worldwide to
AstraZeneca through Oxford University Innovation, or OUI. Vaccitech
is entitled to receive a share of all milestones and royalty income
received by OUI from AstraZeneca.
Vaccitech Media contacts:Katja Stout, Scius
Communications (EU)Direct: +44 (0)
7789435990Email: katja@sciuscommunications.com
Katie Larch / Robert Flamm, Ph.D., Burns McClellan, Inc.
(U.S.)Email: klarch@burnsmc.com / rflamm@burnsmc.com
Gemma Brown, CFO, VaccitechEmail: IR@vaccitech.co.uk
Vaccitech (NASDAQ:VACC)
過去 株価チャート
から 5 2024 まで 6 2024
Vaccitech (NASDAQ:VACC)
過去 株価チャート
から 6 2023 まで 6 2024